Other Financial Assets

The other financial assets were comprised as follows:

Other Financial Assets

 

 

Dec. 31, 2017

 

Dec. 31, 2018

 

 

Total

Of which current

 

Total

Of which current

 

 

€ million

€ million

 

€ million

€ million

1

Measurement category in accordance with IAS 39; applicable until December 31, 2017
AfS: available for sale; at fair value through other comprehensive income
HtM: held to maturity; at amortized cost
LaR: loans and receivables; at amortized cost

2

Measurement category in accordance with IFRS 9; applicable as of January 1, 2018
AC: at amortized cost
FVTOCI: at fair value through other comprehensive income
FVTPL: at fair value through profit or loss

LaR1

 

1,718

1,501

 

AfS1

 

2,728

1,502

 

of which debt instruments

 

2,463

1,499

 

of which equity instruments

 

265

3

 

HtM1

 

57

15

 

AC2

 

 

430

285

FVTPL2

 

 

2,355

665

of which debt instruments

 

 

1,759

665

of which equity instruments

 

 

596

FVTOCI2

 

 

330

of which equity instruments (no recycling)

 

 

330

Receivables from derivatives

 

647

509

 

253

216

Receivables under lease agreements

 

13

2

 

10

Total

 

5,163

3,529

 

3,378

1,166

The AC category included €270 million (2017, LaR category: €1,390 million) in bank deposits. No material impairment losses were recognized for expected credit losses in 2018.

The debt instruments in the FVTPL category included capital of €643 million (2017, AfS category: €605 million) provided to Bayer-Pensionskasse VVaG (Bayer-Pensionskasse) for its effective initial fund, and jouissance right capital (Genussrechtskapital) of €152 million (2017, AfS category: €152 million), also provided to Bayer-Pensionskasse. Also reported in this category were investments of €598 million (2017, AfS category: €1,497 million) in money market funds.

The equity instruments in the FVTPL category comprised the interest in Covestro AG.

The equity instruments in the FVTOCI category comprised the following investments:

Equity Instruments Measured at Fair Value Through Other Comprehensive Income

Company name

 

Fair value as of Dec. 31, 20171

 

Fair value as of Dec. 31, 2018

1

In 2017, equity instruments were recognized in the AfS category in accordance with IAS 39.

CRISPR Therapeutics AG, Switzerland

 

101

 

143

Innovative Seed Solutions LLC, U.S.A.

 

 

41

Flagship Ventures Fund V, L.P., U.S.A.

 

12

 

20

Medopad Ltd., U.K.

 

 

13

Hokusan Co. Ltd., Japan

 

6

 

12

Other investments

 

146

 

101

Total

 

265

 

330

No material equity investments were deconsolidated in 2018 and no material dividends were received.

Further information on the accounting for receivables from derivatives is given in Note “Financial instruments.”

Compare to Last Year